FLGT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Fulgent Genetics Inc (FLGT) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks clear positive momentum, has mixed financial performance, and no significant trading signals or catalysts to suggest a strong entry point. Holding or exploring other opportunities might be better suited for the investor's profile.
The stock shows mixed technical signals. The MACD histogram is positive at 0.24, but contracting, indicating weakening momentum. RSI is neutral at 29.403, and moving averages are converging, showing no clear trend. Key support is at 15.202, and resistance is at 16.707. The stock is currently trading near support levels.
The financials show YoY revenue growth of 9.34%, and net income has improved significantly, up 297.72% YoY, though still negative. Analysts maintain a Buy rating, with a revised price target of $22, indicating potential upside from the current price.
No recent news or congress trading data to provide additional positive sentiment.
In Q4 2025, revenue increased to $83.34M (up 9.34% YoY), net income improved to -$23.42M (up 297.72% YoY), and EPS increased to -0.76 (up 300% YoY). However, gross margin dropped to 36.67% (down 6.41% YoY), indicating cost pressures.
UBS recently lowered the price target from $35 to $22 but maintained a Buy rating, suggesting optimism despite the lower valuation.
